Molecular chaperones as rational drug targets for parkinson's disease therapeutics

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 6, 2010, Pages 741-753

  Kalia, S K ^a,b   Kalia, L V ^a,b   McLean, P J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bcl 2 associated athanogene (BAG) family; C terminal Hsp70 interacting protein (CHIP); chaperones; co chaperones; heat shock protein (Hsp); Hsp90 inhibitors; neurodegeneration; Parkinson's disease

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ARIMOCLOMOL; AROMATIC LEVO AMINO ACID DECARBOXYLASE; AT 001; AT 1001; AT 2101; AT 2220; BAG 1 PROTEIN; BAG 5 PROTEIN; CELL PROTEIN; CHAPERONE; CHIP PROTEIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 104; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIP PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; SNX 2112; STA 9090; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TREHALOSE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BASAL GANGLION; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG INHIBITION; DRUG TARGETING; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUNTINGTON CHOREA; LEWY BODY; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN FOLDING; PROTEIN FUNCTION; SUBSTANTIA NIGRA; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 78649239916     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793237386     Document Type: Article

References (171)

1. Lang, A.E.; Lozano, A.M. Parkinson's disease. First of two parts.N. Engl. J. Med., 1998, 339(15), 1044-1053.
2. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
3. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. alpha-Synuclein in filamentous inclusions of Lewybodies from Parkinson's disease and dementia with lewy bodies.Proc. Natl. Acad. Sci. USA, 1998, 95(11), 6469-6473.
4. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S.W.; Hernandez, D.G.; Kruger, R.; Federoff, M.; Klein, C.; Goate, A.; Perlmutter, J.; Bonin, M.; Nalls, M.A.; Illig, T.; Gieger, C.; Houlden, H.; Steffens, M.; Okun, M.S.; Racette, B.A.; Cookson, M.R.; Foote, K.D.; Fernandez, H.H.; Traynor, B.J.; Schreiber, S.; Arepalli, S.; Zonozi, R.; Gwinn, K.; van der, B.M.; Lopez, G.; Chanock, S.J.; Schatzkin, A.; Park, Y.; Hollenbeck, A.; Gao, J.; Huang, X.; Wood, N.W.; Lorenz, D.; Deuschl, G.; Chen, H.; Riess, O.; Hardy, J.A.; Singleton, A.B.; Gasser, T. Genome-wideassociation study reveals genetic risk underlying Parkinson'sdisease. Nat. Genet., 2009, 41(12), 1308-1312.
5. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; Tomiyama, H.; Nakashima, K.; Hasegawa, K.; Obata, F.; Yoshikawa, T.; Kawakami, H.; Sakoda, S.; Yamamoto, M.; Hattori, N.; Murata, M.; Nakamura, Y.; Toda, T. Genome-wideassociation study identifies common variants at four loci as geneticrisk factors for Parkinson's disease. Nat. Genet., 2009, 41(12), 1303-1307.
6. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms andmodels. Neuron, 2003, 39(6), 889-909.
7. Beal, M.F. Mitochondria, oxidative damage, and inflammation inParkinson's disease. Ann. NY Acad. Sci., 2003, 991, 120-131.
8. Fiskum, G.; Starkov, A.; Polster, B.M.; Chinopoulos, C.Mitochondrial mechanisms of neural cell death and neuroprotectiveinterventions in Parkinson's disease. Ann. NY Acad. Sci., 2003, 991, 111-119.
9. Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration inneurodegeneration: cause, effect, or association? J. Clin. Invest., 2003, 111(2), 163-169.
10. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol., 2003, 53(Suppl 3), 26-36.
11. Aharon-Peretz, J.; Rosenbaum, H.; Gershoni-Baruch, R. Mutationsin the glucocerebrosidase gene and Parkinson's disease inAshkenazi Jews. N. Engl. J. Med. 2004, 351(19), 1972-1977.
12. Hung, A. Y.; Schwarzschild, M. A. Clinical trials for neuroprotect-ion in Parkinson's disease: overcoming angst and futility? Curr.Opin. Neurol., 2007, 20(4), 477-483.
13. Goloubinoff, P.; De Los, R.P. The mechanism of Hsp70chaperones:(entropic) pulling the models together. TrendsBiochem. Sci., 2007, 32(8), 372-380.
14. Sherman, M.Y.; Goldberg, A.L. Cellular defenses against unfoldedproteins: a cell biologist thinks about neurodegenerative diseases. Neuron, 2001, 29(1), 15-32.
15. Kon, M.; Cuervo, A.M. Chaperone-mediated autophagy in healthand disease. FEBS Lett., 2010, 584(7), 1399-1404.
16. Auluck, P.K.; Chan, H.Y.; Trojanowski, J.Q.; Lee, V.M.; Bonini, N.M. Chaperone suppression of alpha-synuclein toxicity in aDrosophila model for Parkinson's disease. Science, 2002, 295(5556), 865-868.
17. Kalia, S.K.; Lee, S.; Smith, P.D.; Liu, L.; Crocker, S.J.; Thorarinsdottir, T.E.; Glover, J.R.; Fon, E.A.; Park, D.S.; Lozano, A.M. BAG5 inhibits parkin and enhances dopaminergic neurondegeneration. Neuron, 2004, 44(6), 931-945.
18. Klucken, J.; Shin, Y.; Masliah, E.; Hyman, B.T.; McLean, P.J.Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J. Biol.Chem., 2004, 279(24), 25497-25502.
19. McLean, P.J.; Kawamata, H.; Shariff, S.; Hewett, J.; Sharma, N.; Ueda, K.; Breakefield, X.O.; Hyman, B.T. TorsinA and heat shockproteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem., 2002, 83(4), 846-854.
20. Sharma, N.; Hewett, J.; Ozelius, L.J.; Ramesh, V.; McLean, P.J.; Breakefield, X.O.; Hyman, B.T. A close association of torsinA andalpha-synuclein in Lewy bodies: a fluorescence resonance energytransfer study. Am. J. Pathol., 2001, 159(1), 339-344.
21. Yvert, G.; Lindenberg, K.S.; Picaud, S.; Landwehrmeyer, G.B.; Sahel, J.A.; Mandel, J.L. Expanded polyglutamines induceneurodegeneration and trans-neuronal alterations in cerebellum andretina of SCA7 transgenic mice. Hum. Mol. Genet., 2000, 9(17), 2491-2506.
22. Waelter, S.; Boeddrich, A.; Lurz, R.; Scherzinger, E.; Lueder, G.; Lehrach, H.; Wanker, E.E. Accumulation of mutant huntingtinfragments in aggresome-like inclusion bodies as a result ofinsufficient protein degradation. Mol. Biol. Cell, 2001, 12(5), 1393-1407.
23. Stenoien, D.L.; Cummings, C.J.; Adams, H.P.; Mancini, M.G.; Patel, K.; DeMartino, G.N.; Marcelli, M.; Weigel, N.L.; Mancini, M.A. Polyglutamine-expanded androgen receptors form aggregatesthat sequester heat shock proteins, proteasome components andSRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol.Genet., 1999, 8(5), 731-741.
24. Kopito, R.R. Aggresomes, inclusion bodies and proteinaggregation. Trends Cell Biol., 2000, 10(12), 524-530.
25. Cummings, C.J.; Mancini, M.A.; Antalffy, B.; DeFranco, D.B.; Orr, H.T.; Zoghbi, H.Y. Chaperone suppression of aggregation andaltered subcellular proteasome localization imply proteinmisfolding in SCA1. Nat. Genet., 1998, 19(2), 148-154.
26. Chai, Y.; Koppenhafer, S.L.; Bonini, N.M.; Paulson, H.L. Analysisof the role of heat shock protein(Hsp) molecular chaperones inpolyglutamine disease. J. Neurosci., 1999, 19(23), 10338-10347.
27. Berke, S.J.; Paulson, H.L. Protein aggregation and the ubiquitinproteasome pathway: gaining the UPPer hand onneurodegeneration. Curr. Opin. Genet. Dev., 2003, 13(3), 253-261.
28. Ritossa, F. A new puffing pattern induced by temperature shockand DNP in Drosophila. Experientia, 1962, 18, 571-573.
29. Tissieres, A.; Mitchell, H.K.; Tracy, U.M. Protein synthesis insalivary glands of Drosophila melanogaster: relation tochromosome puffs. J. Mol. Biol., 1974, 84(3), 389-398.
30. Sakahira, H.; Breuer, P.; Hayer-Hartl, M.K.; Hartl, F.U. Molecularchaperones as modulators of polyglutamine protein aggregationand toxicity. Proc. Natl. Acad. Sci. USA, 2002, 99(Suppl 4), 16412-16418.
31. Witt, S.N. Hsp70 molecular chaperones and Parkinson's disease.Biopolymers, 2010, 93(3), 218-228.
32. Fink, A.L. Chaperone-mediated protein folding. Physiol. Rev., 1999, 79(2), 425-449.
33. Beissinger, M.; Buchner, J. How chaperones fold proteins. Biol.Chem., 1998, 379(3), 245-259.
34. Bukau, B.; Horwich, A.L. The Hsp70 and Hsp60 chaperonemachines. Cell, 1998, 92(3), 351-366.
35. Hartl, F.U.; Hayer-Hartl, M. Molecular chaperones in the cytosol:from nascent chain to folded protein. Science, 2002, 295(5561), 1852-1858.
36. Nollen, E.A.; Morimoto, R.I. Chaperoning signaling pathways:molecular chaperones as stress-sensing 'heat shock' proteins. J. CellSci., 2002, 115(Pt 14), 2809-2816.
37. Kelley, W. L. Molecular chaperones: How J domains turn onHsp70s. Curr. Biol., 1999, 9(8), 305-308.
38. Hohfeld, J. Regulation of the heat shock conjugate Hsc70 in themammalian cell: the characterization of the anti-apoptotic proteinBAG-1 provides novel insights. Biol. Chem., 1998, 379(3), 269-274.
39. Hohfeld, J.; Minami, Y.; Hartl, F.U. Hip, a novel cochaperoneinvolved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell, 1995, 83(4), 589-598.
40. Hohfeld, J.; Jentsch, S. GrpE-like regulation of the hsc70chaperone by the anti-apoptotic protein BAG-1. EMBO J., 1997, 16(20), 6209-6216.
41. Zeiner, M.; Gebauer, M.; Gehring, U. Mammalian protein RAP46:an interaction partner and modulator of 70 kDa heat shock proteins. EMBO J., 1997, 16(18), 5483-5490.
42. Takayama, S.; Sato, T.; Krajewski, S.; Kochel, K.; Irie, S.; Millan, J.A.; Reed, J.C. Cloning and functional analysis of BAG-1: a novelBcl-2-binding protein with anti-cell death activity. Cell, 1995, 80(2), 279-284.
43. Sondermann, H.; Scheufler, C.; Schneider, C.; Hohfeld, J.; Hartl, F.U.; Moarefi, I. Structure of a Bag/Hsc70 complex: convergentfunctional evolution of Hsp70 nucleotide exchange factors. Science, 2001, 291(5508), 1553-1557.
44. Gebauer, M.; Zeiner, M.; Gehring, U. Proteins interacting with themolecular chaperone hsp70/hsc70: physical associations and effectson refolding activity. FEBS Lett., 1997, 417(1), 109-113.
45. Bimston, D.; Song, J.; Winchester, D.; Takayama, S.; Reed, J.C.; Morimoto, R.I. BAG-1, a negative regulator of Hsp70 chaperoneactivity, uncouples nucleotide hydrolysis from substrate release. EMBO J., 1998, 17(23), 6871-6878.
46. Cummings, C.J.; Sun, Y.; Opal, P.; Antalffy, B.; Mestril, R.; Orr, H.T.; Dillmann, W.H.; Zoghbi, H.Y. Over-expression of inducibleHSP70 chaperone suppresses neuropathology and improves motorfunction in SCA1 mice. Hum. Mol. Genet., 2001, 10(14), 1511-1518.
47. Kazemi-Esfarjani, P.; Benzer, S. Genetic suppression ofpolyglutamine toxicity in Drosophila. Science, 2000, 287(5459), 1837-1840.
48. Chan, H.Y.; Warrick, J.M.; Gray-Board, G.L.; Paulson, H.L.; Bonini, N.M. Mechanisms of chaperone suppression ofpolyglutamine disease: selectivity, synergy and modulation ofprotein solubility in Drosophila. Hum. Mol. Genet., 2000, 9(19), 2811-2820.
49. Warrick, J.M.; Chan, H.Y.; Gray-Board, G.L.; Chai, Y.; Paulson, H.L.; Bonini, N.M. Suppression of polyglutamine-mediatedneurodegeneration in Drosophila by the molecular chaperoneHSP70. Nat. Genet., 1999, 23(4), 425-428.
50. Wu, Y.R.; Wang, C.K.; Chen, C.M.; Hsu, Y.; Lin, S.J.; Lin, Y.Y.; Fung, H.C.; Chang, K.H.; Lee-Chen, G.J. Analysis of heat-shockprotein 70 gene polymorphisms and the risk of Parkinson's disease.Hum. Genet., 2004, 114(3), 236-241.
51. Flower, T.R.; Chesnokova, L.S.; Froelich, C.A.; Dixon, C.; Witt, S.N. Heat shock prevents alpha-synuclein-induced apoptosis in ayeast model of Parkinson's disease. J. Mol. Biol., 2005, 351(5), 1081-1100.
52. Quigney, D.J.; Gorman, A.M.; Samali, A. Heat shock protectsPC12 cells against MPP+ toxicity. Brain Res., 2003, 993(1-2), 133-139.
53. Dong, Z.; Wolfer, D.P.; Lipp, H.P.; Bueler, H. Hsp70 gene transferby adeno-associated virus inhibits MPTP-induced nigrostriataldegeneration in the mouse model of Parkinson disease. Mol. Ther., 2005, 11(1), 80-88.
54. Jung, A.E.; Fitzsimons, H.L.; Bland, R.J.; During, M.J.; Young, D.HSP70 and constitutively active HSF1 mediate protection againstCDCrel-1-mediated toxicity. Mol. Ther., 2008, 16(6), 1048-1055.
55. Klucken, J.; Shin, Y.; Hyman, B.T.; McLean, P.J. A single aminoacid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem. Biophys. Res.Commun., 2004, 325(1), 367-373.
56. Klucken, J.; Outeiro, T.F.; Nguyen, P.; McLean, P.J.; Hyman, B.T. Detection of novel intracellular alpha-synuclein oligomeric speciesby fluorescence lifetime imaging. FASEB J., 2006, 20(12), 2050-2057.
57. Luk, K.C.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M. Interactionsbetween Hsp70 and the hydrophobic core of alpha-synuclein inhibitfibril assembly. Biochemistry, 2008, 47(47), 12614-12625.
58. Huang, C.; Cheng, H.; Hao, S.; Zhou, H.; Zhang, X.; Gao, J.; Sun, Q. H.; Hu, H.; Wang, C.C. Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverseintermediates. J. Mol. Biol., 2006, 364(3), 323-336.
59. Outeiro, T.F.; Putcha, P.; Tetzlaff, J.E.; Spoelgen, R.; Koker, M.; Carvalho, F.; Hyman, B.T.; McLean, P.J. Formation of toxicoligomeric alpha-synuclein species in living cells. PLoS One, 2008, 3(4), e1867.
60. McLean, P.J.; Klucken, J.; Shin, Y.; Hyman, B.T. Geldanamycininduces Hsp70 and prevents alpha-synuclein aggregation andtoxicity in vitro. Biochem. Biophys. Res. Commun., 2004, 321(3), 665-669.
61. Roodveldt, C.; Bertoncini, C.W.; Andersson, A.; van der Goot, A.T.; Hsu, S.T.; Fernandez-Montesinos, R.; de, J.J.; van Ham, T.J.; Nollen, E.A.; Pozo, D.; Christodoulou, J.; Dobson, C.M. Chaperone proteostasis in Parkinson's disease: stabilization of theHsp70/alpha-synuclein complex by hip. EMBO J., 2009, 28(23), 3758-3770.
62. Imai, Y.; Soda, M.; Hatakeyama, S.; Akagi, T.; Hashikawa, T.; Nakayama, K.I.; Takahashi, R. CHIP is associated with Parkin, agene responsible for familial Parkinson's disease, and enhances itsubiquitin ligase activity. Mol. Cell., 2002, 10(1), 55-67.
63. Yang, F.; Yang, Y.P.; Mao, C.J.; Cao, B.Y.; Cai, Z.L.; Shi, J.J.; Huang, J.Z.; Zhang, P.; Liu, C.F. Role of autophagy andproteasome degradation pathways in apoptosis of PC12 cellsoverexpressing human alpha-synuclein. Neurosci. Lett., 2009, 454(3), 203-208.
64. Tsai, Y.C.; Fishman, P.S.; Thakor, N.V.; Oyler, G.A. Parkinfacilitates the elimination of expanded polyglutamine proteins andleads to preservation of proteasome function. J. Biol. Chem., 2003, 278(24), 22044-22055.
65. Chavez Z.A.T.; Loranger, A.; Marceau, N.; Theriault, J.R.; Lambert, H.; Landry, J. Distinct chaperone mechanisms can delaythe formation of aggresomes by the myopathy-causing R120GalphaB-crystallin mutant. Hum. Mol. Genet., 2003, 12(13), 1609-1620.
66. Bailey, C.K.; Andriola, I.F.; Kampinga, H.H.; Merry, D.E. Molecular chaperones enhance the degradation of expandedpolyglutamine repeat androgen receptor in a cellular model ofspinal and bulbar muscular atrophy. Hum. Mol. Genet., 2002, 11(5), 515-523.
67. Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Pagoulatos, G.; Angelidis, C.; Kusakabe, M.; Yoshiki, A.; Kobayashi, Y.; Doyu, M.; Sobue, G. Heat shock protein 70 chaperoneoverexpression ameliorates phenotypes of the spinal and bulbarmuscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci., 2003, 23(6), 2203-2211.
68. Murata, S.; Minami, Y.; Minami, M.; Chiba, T.; Tanaka, K. CHIPis a chaperone-dependent E3 ligase that ubiquitylates unfoldedprotein. EMBO Rep., 2001, 2(12), 1133-1138.
69. Murata, S.; Chiba, T.; Tanaka, K. CHIP: a quality-control E3 ligasecollaborating with molecular chaperones. Int. J. Biochem. CellBiol., 2003, 35(5), 572-578.
70. Meacham, G.C.; Patterson, C.; Zhang, W.; Younger, J.M.; Cyr, D.M. The Hsc70 co-chaperone CHIP targets immature CFTR forproteasomal degradation. Nat. Cell Biol., 2001, 3(1), 100-105.
71. Luders, J.; Demand, J.; Hohfeld, J. The ubiquitin-related BAG-1provides a link between the molecular chaperones Hsc70/Hsp70and the proteasome. J. Biol. Chem., 2000, 275(7), 4613-4617.
72. Hung, W.J.; Roberson, R.S.; Taft, J.; Wu, D.Y. Human BAG-1proteins bind to the cellular stress response protein GADD34 andinterfere with GADD34 functions. Mol. Cell. Biol., 2003, 23(10), 3477-3486.
73. Demand, J.; Alberti, S.; Patterson, C.; Hohfeld, J. Cooperation of aubiquitin domain protein and an E3 ubiquitin ligase duringchaperone/proteasome coupling. Curr. Biol., 2001, 11(20), 1569-1577.
74. Connell, P.; Ballinger, C.A.; Jiang, J.; Wu, Y.; Thompson, L.J.; Hohfeld, J.; Patterson, C. The co-chaperone CHIP regulates proteintriage decisions mediated by heat-shock proteins. Nat. Cell Biol., 2001, 3(1), 93-96.
75. Cardozo, C.P.; Michaud, C.; Ost, M.C.; Fliss, A.E.; Yang, E.; Patterson, C.; Hall, S.J.; Caplan, A.J. C-terminal Hsp-interactingprotein slows androgen receptor synthesis and reduces its rate ofdegradation. Arch. Biochem. Biophys., 2003, 410(1), 134-140.
76. Alberti, S.; Demand, J.; Esser, C.; Emmerich, N.; Schild, H.; Hohfeld, J. Ubiquitylation of BAG-1 suggests a novel regulatorymechanism during the sorting of chaperone substrates to theproteasome. J. Biol. Chem., 2002, 277(48), 45920-45927.
77. Saleh, A.; Srinivasula, S.M.; Balkir, L.; Robbins, P.D.; Alnemri, E.S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat.Cell Biol., 2000, 2(8), 476-483.
78. Ravagnan, L.; Gurbuxani, S.; Susin, S.A.; Maisse, C.; Daugas, E.; Zamzami, N.; Mak, T.; Jaattela, M.; Penninger, J.M.; Garrido, C.; Kroemer, G. Heat-shock protein 70 antagonizes apoptosis-inducingfactor. Nat. Cell Biol., 2001, 3(9), 839-843.
79. Jaattela, M.; Wissing, D.; Kokholm, K.; Kallunki, T.; Egeblad, M.Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J., 1998, 17(21), 6124-6134.
80. Beere, H.M.; Wolf, B.B.; Cain, K.; Mosser, D.D.; Mahboubi, A.; Kuwana, T.; Tailor, P.; Morimoto, R.I.; Cohen, G.M.; Green, D.R. Heat-shock protein 70 inhibits apoptosis by preventing recruitmentof procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol., 2000, 2(8), 469-475.
81. Volloch, V.; Mosser, D.D.; Massie, B.; Sherman, M.Y. Reducedthermotolerance in aged cells results from a loss of an hsp72-mediated control of JNK signaling pathway. Cell StressChaperones, 1998, 3(4), 265-271.
82. Park, H.S.; Lee, J.S.; Huh, S.H.; Seo, J.S.; Choi, E.J. Hsp72functions as a natural inhibitory protein of c-Jun N-terminal kinase. EMBO J., 2001, 20(3), 446-456.
83. Mosser, D.D.; Caron, A.W.; Bourget, L.; Denis-Larose, C.; Massie, B. Role of the human heat shock protein hsp70 in protectionagainst stress-induced apoptosis. Mol. Cell. Biol., 1997, 17(9), 5317-5327.
84. Mosser, D.D.; Caron, A.W.; Bourget, L.; Meriin, A.B.; Sherman, M.Y.; Morimoto, R.I.; Massie, B. The chaperone function of hsp70is required for protection against stress-induced apoptosis. Mol.Cell. Biol., 2000, 20(19), 7146-7159.
85. Gabai, V.L.; Meriin, A.B.; Mosser, D.D.; Caron, A.W.; Rits, S.; Shifrin, V.I.; Sherman, M.Y. Hsp70 prevents activation of stresskinases. A novel pathway of cellular thermotolerance. J. Biol.Chem., 1997, 272(29), 18033-18037.
86. Gabai, V.L.; Meriin, A.B.; Yaglom, J.A.; Volloch, V.Z.; Sherman, M.Y. Role of Hsp70 in regulation of stress-kinase JNK:implications in apoptosis and aging. FEBS Lett., 1998, 438(1-2), 1-4.
87. Moore, D.J.; West, A.B.; Dikeman, D.A.; Dawson, V.L.; Dawson, T.M. Parkin mediates the degradation-independent ubiquitinationof Hsp70. J. Neurochem., 2008, 105(5), 1806-1819.
88. Liu, M.; Aneja, R.; Sun, X.; Xie, S.; Wang, H.; Wu, X.; Dong, J.T.; Li, M.; Joshi, H.C.; Zhou, J. Parkin regulates Eg5 expression byHsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J. Biol. Chem., 2008, 283(51), 35783-35788.
89. Nardai, G.; Csermely, P.; Soti, C. Chaperone function andchaperone overload in the aged. A preliminary analysis. Exp.Gerontol., 2002, 37(10-11), 1257-1262.
90. Gutsmann-Conrad, A.; Heydari, A.R.; You, S.; Richardson, A. Theexpression of heat shock protein 70 decreases with cellularsenescence in vitro and in cells derived from young and old humansubjects. Exp. Cell Res., 1998, 241(2), 404-413.
91. Okado-Matsumoto, A.; Fridovich, I. Amyotrophic lateral sclerosis:a proposed mechanism. Proc. Natl. Acad. Sci. USA, 2002, 99(13), 9010-9014.
92. Takayama, S.; Reed, J.C. Molecular chaperone targeting andregulation by BAG family proteins. Nat. Cell Biol., 2001, 3(10), 237-241.
93. Zeiner, M.; Gehring, U. A protein that interacts with members ofthe nuclear hormone receptor family: identification and cDNAcloning. Proc. Natl. Acad. Sci. USA, 1995, 92(25), 11465-11469.
94. Zeiner, M.; Niyaz, Y.; Gehring, U. The hsp70-associating proteinHap46 binds to DNA and stimulates transcription. Proc. Natl.Acad. Sci. USA, 1999, 96(18), 10194-10199.
95. Takayama, S.; Bimston, D.N.; Matsuzawa, S.; Freeman, B.C.; Aime-Sempe, C.; Xie, Z.; Morimoto, R.I.; Reed, J.C. BAG-1modulates the chaperone activity of Hsp70/Hsc70. EMBO J., 1997, 16(16), 4887-4896.
96. Nollen, E.A.; Brunsting, J.F.; Song, J.; Kampinga, H.H.; Morimoto, R.I. Bag1 functions in vivo as a negative regulator of Hsp70chaperone activity. Mol. Cell. Biol., 2000, 20(3), 1083-1088.
97. Nollen, E.A.; Kabakov, A.E.; Brunsting, J.F.; Kanon, B.; Hohfeld, J.; Kampinga, H.H. Modulation of in vivo HSP70 chaperoneactivity by Hip and Bag-1. J. Biol. Chem., 2001, 276(7), 4677-4682.
98. Takayama, S.; Xie, Z.; Reed, J.C. An evolutionarily conservedfamily of Hsp70/Hsc70 molecular chaperone regulators. J. Biol.Chem., 1999, 274(2), 781-786.
99. Doong, H.; Price, J.; Kim, Y.S.; Gasbarre, C.; Probst, J.; Liotta, L.A.; Blanchette, J.; Rizzo, K.; Kohn, E. CAIR-1/BAG-3 forms anEGF-regulated ternary complex with phospholipase C-gamma andHsp70/Hsc70. Oncogene, 2000, 19(38), 4385-4395.
100. Briknarova, K.; Takayama, S.; Homma, S.; Baker, K.; Cabezas, E.; Hoyt, D.W.; Li, Z.; Satterthwait, A.C.; Ely, K.R. BAG4/SODDprotein contains a short BAG domain. J. Biol. Chem., 2002, 277(34), 31172-31178.
101. Thress, K.; Song, J.; Morimoto, R.I.; Kornbluth, S. Reversibleinhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J., 2001, 20(5), 1033-1041.
102. Song, J.; Takeda, M.; Morimoto, R.I. Bag1-Hsp70 mediates aphysiological stress signalling pathway that regulates Raf-1/ERKand cell growth. Nat. Cell Biol., 2001, 3(3), 276-282.
103. Matsuzawa, S.; Takayama, S.; Froesch, B.A.; Zapata, J.M.; Reed, J.C. p53-inducible human homologue of Drosophila seven inabsentia(Siah) inhibits cell growth: suppression by BAG-1. EMBOJ., 1998, 17(10), 2736-2747.
104. Lorick, K.L.; Jensen, J.P.; Fang, S.; Ong, A.M.; Hatakeyama, S.; Weissman, A.M. RING fingers mediate ubiquitin-conjugatingenzyme(E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA, 1999, 96(20), 11364-11369.
105. Engelender, S.; Kaminsky, Z.; Guo, X.; Sharp, A.H.; Amaravi, R.K.; Kleiderlein, J.J.; Margolis, R.L.; Troncoso, J.C.; Lanahan, A.A.; Worley, P.F.; Dawson, V.L.; Dawson, T.M.; Ross, C.A. Synphilin-1 associates with alpha-synuclein and promotes theformation of cytosolic inclusions. Nat. Genet., 1999, 22(1), 110-114.
106. Szargel, R.; Rott, R.; Eyal, A.; Haskin, J.; Shani, V.; Balan, L.; Wolosker, H.; Engelender, S. Synphilin-1A inhibits seven inabsentia homolog(SIAH) and modulates alpha-synucleinmonoubiquitylation and inclusion formation. J. Biol. Chem., 2009, 284(17), 11706-11716.
107. Rott, R.; Szargel, R.; Haskin, J.; Shani, V.; Shainskaya, A.; Manov, I.; Liani, E.; Avraham, E.; Engelender, S. Monoubiquitylation ofalpha-synuclein by seven in absentia homolog(SIAH) promotes itsaggregation in dopaminergic cells. J. Biol. Chem., 2008, 283(6), 3316-3328.
108. Nagano, Y.; Yamashita, H.; Takahashi, T.; Kishida, S.; Nakamura, T.; Iseki, E.; Hattori, N.; Mizuno, Y.; Kikuchi, A.; Matsumoto, M. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J.Biol. Chem., 2003, 23, 23.
109. Arndt, V.; Daniel, C.; Nastainczyk, W.; Alberti, S.; Hohfeld, J. BAG-2 acts as an inhibitor of the chaperone-associated ubiquitinligase CHIP. Mol. Biol. Cell, 2005, 16(12), 5891-5900.
110. Dai, Q.; Qian, S.B.; Li, H.H.; McDonough, H.; Borchers, C.; Huang, D.; Takayama, S.; Younger, J.M.; Ren, H.Y.; Cyr, D.M.; Patterson, C. Regulation of the cytoplasmic quality control proteindegradation pathway by BAG2. J. Biol. Chem., 2005, 280(46), 38673-38681.
111. Carrettiero, D.C.; Hernandez, I.; Neveu, P.; Papagiannakopoulos, T.; Kosik, K.S. The cochaperone BAG2 sweeps paired helicalfilamentinsoluble tau from the microtubule. J. Neurosci., 2009, 29(7), 2151-2161.
112. Doong, H.; Rizzo, K.; Fang, S.; Kulpa, V.; Weissman, A.M.; Koh, E.C. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperonecomplex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J. Biol. Chem., 2003, 278(31), 28490-28500.
113. Carra, S.; Seguin, S.J.; Landry, J. HspB8 and Bag3: a newchaperone complex targeting misfolded proteins tomacroautophagy. Autophagy, 2008, 4(2), 237-239.
114. Carra, S.; Seguin, S. J.; Lambert, H.; Landry, J. HspB8 chaperoneactivity toward poly(Q)-containing proteins depends on itsassociation with Bag3, a stimulator of macroautophagy. J. Biol.Chem., 2008, 283(3), 1437-1444.
115. Gamerdinger, M.; Hajieva, P.; Kaya, A.M.; Wolfrum, U.; Hartl, F.U.; Behl, C. Protein quality control during aging involvesrecruitment of the macroautophagy pathway by BAG3. EMBO J., 2009, 28(7), 889-901.
116. Ballinger, C.A.; Connell, P.; Wu, Y.; Hu, Z.; Thompson, L.J.; Yin, L.Y.; Patterson, C. Identification of CHIP, a novel tetratricopeptiderepeat-containing protein that interacts with heat shock proteins andnegatively regulates chaperone functions. Mol. Cell. Biol., 1999, 19(6), 4535-4545.
117. Kampinga, H.H.; Kanon, B.; Salomons, F.A.; Kabakov, A.E.; Patterson, C. Overexpression of the cochaperone CHIP enhancesHsp70-dependent folding activity in mammalian cells. Mol. Cell.Biol., 2003, 23(14), 4948-4958.
118. Jiang, J.; Ballinger, C.A.; Wu, Y.; Dai, Q.; Cyr, D.M.; Hohfeld, J.; Patterson, C. CHIP is a U-box-dependent E3 ubiquitin ligase:identification of Hsc70 as a target for ubiquitylation. J. Biol.Chem., 2001, 276(46), 42938-42944.
119. Shin, Y.; Klucken, J.; Patterson, C.; Hyman, B.T.; McLean, P.J. The co-chaperone carboxyl terminus of Hsp70-interactingprotein(CHIP) mediates alpha-synuclein degradation decisionsbetween proteasomal and lysosomal pathways. J. Biol. Chem., 2005, 280(25), 23727-23734.
120. Petrucelli, L.; Dickson, D.; Kehoe, K.; Taylor, J.; Snyder, H.; Grover, A.; De, L.M.; McGowan, E.; Lewis, J.; Prihar, G.; Kim, J.; Dillmann, W.H.; Browne, S.E.; Hall, A.; Voellmy, R.; Tsuboi, Y.; Dawson, T.M.; Wolozin, B.; Hardy, J.; Hutton, M. CHIP andHsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet., 2004, 13(7), 703-714.
121. Tetzlaff, J.E.; Putcha, P.; Outeiro, T.F.; Ivanov, A.; Berezovska, O.; Hyman, B.T.; McLean, P.J. CHIP targets toxic alpha-Synucleinoligomers for degradation. J. Biol. Chem., 2008, 283(26), 17962-17968.
122. Ko, H.S.; Bailey, R.; Smith, W.W.; Liu, Z.; Shin, J.H.; Lee, Y.I.; Zhang, Y.J.; Jiang, H.; Ross, C.A.; Moore, D.J.; Patterson, C.; Petrucelli, L.; Dawson, T.M.; Dawson, V.L. CHIP regulatesleucine-rich repeat kinase-2 ubiquitination, degradation, andtoxicity. Proc. Natl. Acad. Sci. USA, 2009, 106(8), 2897-2902.
123. Ding, Q.; Lewis, J.J.; Strum, K.M.; Dimayuga, E.; Bruce-Keller, A.J.; Dunn, J.C.; Keller, J.N. Polyglutamine expansion, proteinaggregation, proteasome activity, and neural survival. J. Biol.Chem., 2002, 277(16), 13935-13942.
124. Dai, Q.; Zhang, C.; Wu, Y.; McDonough, H.; Whaley, R.A.; Godfrey, V.; Li, H.H.; Madamanchi, N.; Xu, W.; Neckers, L.; Cyr, D.; Patterson, C. CHIP activates HSF1 and confers protectionagainst apoptosis and cellular stress. EMBO J., 2003, 22(20), 5446-5458.
125. Scherzer, C.R.; Eklund, A.C.; Morse, L.J.; Liao, Z.; Locascio, J.J.; Fefer, D.; Schwarzschild, M.A.; Schlossmacher, M.G.; Hauser, M.A.; Vance, J.M.; Sudarsky, L.R.; Standaert, D.G.; Growdon, J.H.; Jensen, R.V.; Gullans, S.R. Molecular markers of earlyParkinson's disease based on gene expression in blood. Proc. Natl.Acad. Sci. USA, 2007, 104(3), 955-960.
126. Hahn, J.S. The Hsp90 chaperone machinery: from structure to drugdevelopment. BMB Rep., 2009, 42(10), 623-630.
127. Johnson, B.D.; Schumacher, R.J.; Ross, E.D.; Toft, D.O. Hopmodulates Hsp70/Hsp90 interactions in protein folding. J. Biol.Chem., 1998, 273(6), 3679-3686.
128. Uryu, K.; Richter-Landsberg, C.; Welch, W.; Sun, E.; Goldbaum, O.; Norris, E.H.; Pham, C.T.; Yazawa, I.; Hilburger, K.; Micsenyi, M.; Giasson, B.I.; Bonini, N.M.; Lee, V.M.; Trojanowski, J.Q. Convergence of heat shock protein 90 with ubiquitin in filamentousalpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol., 2006, 168(3), 947-961.
129. Weihofen, A.; Ostaszewski, B.; Minami, Y.; Selkoe, D.J. Pink1Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin allinfluence the maturation or subcellular distribution of Pink1. Hum.Mol. Genet., 2008, 17(4), 602-616.
130. Ding, X.; Goldberg, M.S. Regulation of LRRK2 stability by the E3ubiquitin ligase CHIP. PLoS One, 2009, 4(6), e5949.
131. Moriwaki, Y.; Kim, Y.J.; Ido, Y.; Misawa, H.; Kawashima, K.; Endo, S.; Takahashi, R. L347P PINK1 mutant that fails to bind toHsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci. Res., 2008, 61(1), 43-48.
132. Wang, L.; Xie, C.; Greggio, E.; Parisiadou, L.; Shim, H.; Sun, L.; Chandran, J.; Lin, X.; Lai, C.; Yang, W.J.; Moore, D.J.; Dawson, T.M.; Dawson, V.L.; Chiosis, G.; Cookson, M.R.; Cai, H. Thechaperone activity of heat shock protein 90 is critical formaintaining the stability of leucine-rich repeat kinase 2. J.Neurosci., 2008, 28(13), 3384-3391.
133. Auluck, P.K.; Bonini, N.M. Pharmacological prevention ofParkinson disease in Drosophila. Nat. Med., 2002, 8(11), 1185-1186.
134. Putcha, P.; Danzer, K.M.; Kranich, L.; Scott, A.; Silinski, M.; Mabbett, S.; Hicks, C.D.; Veal, J.M.; Steed, P.M.; Hyman, B.T.; McLean, P.J. Brain permeable small molecule inhibitors of Hsp90prevent alpha-synuclein oligomer formation and rescue alphasynuclein-induced toxicity. J. Pharmacol. Exp. Ther., 2010, 332(3), 849-857.
135. Dickey, C.A.; Eriksen, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, C.B.; Hutton, M.; Petrucelli, L. Development of a highthroughput drug screening assay for the detection of changes in taulevels -proof of concept with HSP90 inhibitors. Curr. AlzheimerRes., 2005, 2(2), 231-238.
136. Fujikake, N.; Nagai, Y.; Popiel, H.A.; Okamoto, Y.; Yamaguchi, M.; Toda, T. Heat shock transcription factor 1-activatingcompounds suppress polyglutamine-induced neurodegenerationthrough induction of multiple molecular chaperones. J. Biol.Chem., 2008, 283(38), 26188-26197.
137. Shen, H.Y.; He, J.C.; Wang, Y.; Huang, Q.Y.; Chen, J.F. Geldanamycin induces heat shock protein 70 and protects againstMPTP-induced dopaminergic neurotoxicity in mice. J. Biol. Chem., 2005, 280(48), 39962-39969.
138. Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Tanaka, F.; Inukai, A.; Doyu, M.; Sobue, G. 17-AAG, an Hsp90inhibitor, ameliorates polyglutamine-mediated motor neurondegeneration. Nat. Med., 2005, 11(10), 1088-1095.
139. Heath, E.I.; Hillman, D.W.; Vaishampayan, U.; Sheng, S.; Sarkar, F.; Harper, F.; Gaskins, M.; Pitot, H.C.; Tan, W.; Ivy, S.P.; Pili, R.; Carducci, M.A.; Erlichman, C.; Liu, G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res., 2008, 14(23), 7940-7946.
140. Ramanathan, R.K.; Trump, D.L.; Eiseman, J.L.; Belani, C.P.; Agarwala, S.S.; Zuhowski, E.G.; Lan, J.; Potter, D.M.; Ivy, S.P.; Ramalingam, S.; Brufsky, A.M.; Wong, M.K.; Tutchko, S.; Egorin, M.J. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin(17AAG, NSC 330507), anovel inhibitor of heat shock protein 90, in patients with refractoryadvanced cancers. Clin. Cancer Res., 2005, 11(9), 3385-3391.
141. Chiosis, G.; Tao, H. Purine-scaffold Hsp90 inhibitors. IDrugs, 2006, 9(11), 778-782.
142. Cysyk, R.L.; Parker, R.J.; Barchi, J.J., Jr.; Steeg, P.S.; Hartman, N.R.; Strong, J.M. Reaction of geldanamycin and C17-substitutedanalogues with glutathione: product identifications andpharmacological implications. Chem. Res. Toxicol., 2006, 19(3), 376-381.
143. Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; Norton, L.; Rosen, N.; Solit, D.B. SNX2112, a synthetic heat shock protein 90inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res., 2008, 14(1), 240-248.
144. Okawa, Y.; Hideshima, T.; Steed, P.; Vallet, S.; Hall, S.; Huang, K.; Rice, J.; Barabasz, A.; Foley, B.; Ikeda, H.; Raje, N.; Kiziltepe, T.; Yasui, H.; Enatsu, S.; Anderson, K.C. SNX-2112, a selectiveHsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologictumors by abrogating signaling via Akt and ERK. Blood, 2009, 113(4), 846-855.
145. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. TargetingHsp90: small-molecule inhibitors and their clinical development.Curr. Opin. Pharmacol., 2008, 8(4), 370-374.
146. Taldone, T.; Sun, W.; Chiosis, G. Discovery and development ofheat shock protein 90 inhibitors. Bioorg. Med. Chem., 2009, 17(6), 2225-2235.
147. Hanson, B.E.; Vesole, D.H. Retaspimycin hydrochloride(IPI-504):a novel heat shock protein inhibitor as an anticancer agent. ExpertOpin. Investig. Drugs, 2009, 18(9), 1375-1383.
148. Lin, T.Y.; Bear, M.; Du, Z.; Foley, K.P.; Ying, W.; Barsoum, J.; London, C. The novel HSP90 inhibitor STA-9090 exhibits activityagainst Kit-dependent and -independent malignant mast celltumors. Exp. Hematol., 2008, 36(10), 1266-1277.
149. Lanka, V.; Wieland, S.; Barber, J.; Cudkowicz, M. Arimoclomol: apotential therapy under development for ALS. Expert Opin.Investig. Drugs, 2009, 18(12), 1907-1918.
150. Kalmar, B.; Greensmith, L. Activation of the heat shock responsein a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. Cell Mol. Biol.Lett., 2009, 14(2), 319-335.
151. Kalmar, B.; Novoselov, S.; Gray, A.; Cheetham, M.E.; Margulis, B.; Greensmith, L. Late stage treatment with arimoclomol delaysdisease progression and prevents protein aggregation in the SOD1mouse model of ALS. J. Neurochem., 2008, 107(2), 339-350.
152. Kieran, D.; Kalmar, B.; Dick, J.R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, acoinducer of heat shock proteins, delays disease progression inALS mice. Nat. Med., 2004, 10(4), 402-405.
153. Cudkowicz, M.E.; Shefner, J.M.; Simpson, E.; Grasso, D.; Yu, H.; Zhang, H.; Shui, A.; Schoenfeld, D.; Brown, R.H.; Wieland, S.; Barber, J.R. Arimoclomol at dosages up to 300 mg/day is welltolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve, 2008, 38(1), 837-844.
154. [154] Neef, D.W.; Turski, M.L.; Thiele, D.J. Modulation of heat shocktranscription factor 1 as a therapeutic target for small moleculeintervention in neurodegenerative disease. PLoS Biol., 2010, 8(1), e1000291.
155. Christine, C.W.; Starr, P.A.; Larson, P.S.; Eberling, J.L.; Jagust, W.J.; Hawkins, R.A.; VanBrocklin, H.F.; Wright, J.F.; Bankiewicz, K.S.; Aminoff, M.J. Safety and tolerability of putaminal AADCgene therapy for Parkinson disease. Neurology, 2009, 73(20), 1662-1669.
156. Glover, J.R.; Lindquist, S. Hsp104, Hsp70, and Hsp40: a novelchaperone system that rescues previously aggregated proteins. Cell, 1998, 94(1), 73-82.
157. Mosser, D.D.; Ho, S.; Glover, J.R. Saccharomyces cerevisiaeHsp104 enhances the chaperone capacity of human cells andinhibits heat stress-induced proapoptotic signaling. Biochemistry, 2004, 43(25), 8107-8115.
158. Lo, B.C.; Shorter, J.; Regulier, E.; Lashuel, H.; Iwatsubo, T.; Lindquist, S.; Aebischer, P. Hsp104 antagonizes alpha-synucleinaggregation and reduces dopaminergic degeneration in a rat modelof Parkinson disease. J. Clin. Invest., 2008, 118(9), 3087-3097.
159. Manfredsson, F.P.; Lewin, A.S.; Mandel, R.J. RNA knockdown asa potential therapeutic strategy in Parkinson's disease. Gene Ther., 2006, 13(6), 517-524.
160. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetratingpeptides: from molecular mechanisms to therapeutics. Br. J.Pharmacol., 2009, 157(2), 195-206.
161. Lai, Y.; Du, L.; Dunsmore, K.E.; Jenkins, L.W.; Wong, H.R.; Clark, R.S. Selectively increasing inducible heat shock protein 70via TAT-protein transduction protects neurons from nitrosativestress and excitotoxicity. J. Neurochem., 2005, 94(2), 360-366.
162. Nagel, F.; Falkenburger, B.H.; Tonges, L.; Kowsky, S.; Poppelmeyer, C.; Schulz, J.B.; Bahr, M.; Dietz, G.P. Tat-Hsp70protects dopaminergic neurons in midbrain cultures and in thesubstantia nigra in models of Parkinson's disease. J. Neurochem., 2008, 105(3), 853-864.
163. Hou, Y.; Zou, J. Delivery of HSF1(+) protein using HIV-1 TATprotein transduction domain. Mol. Biol. Rep., 2009, 36(8), 2271-2277.
164. Kim, S.A.; Chang, S.; Yoon, J.H.; Ahn, S.G. TAT-Hsp40 inhibitsoxidative stress-mediated cytotoxicity via the inhibition of Hsp70ubiquitination. FEBS Lett., 2008, 582(5), 734-740.
165. Singer, M.A.; Lindquist, S. Multiple effects of trehalose on proteinfolding in vitro and in vivo. Mol. Cell, 1998, 1(5), 639-648.
166. Tanaka, M.; Machida, Y.; Niu, S.; Ikeda, T.; Jana, N.R.; Doi, H.; Kurosawa, M.; Nekooki, M.; Nukina, N. Trehalose alleviatespolyglutamine-mediated pathology in a mouse model ofHuntington disease. Nat. Med., 2004, 10(2), 148-154.
167. Sarkar, S.; Davies, J.E.; Huang, Z.; Tunnacliffe, A.; Rubinsztein, D.C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein.J. Biol. Chem., 2007, 282(8), 5641-5652.
168. Flanagan, J.J.; Rossi, B.; Tang, K.; Wu, X.; Mascioli, K.; Donaudy, F.; Tuzzi, M.R.; Fontana, F.; Cubellis, M.V.; Porto, C.; Benjamin, E.; Lockhart, D.J.; Valenzano, K.J.; Andria, G.; Parenti, G.; Do, H.V. The pharmacological chaperone 1-deoxynojirimycin increasesthe activity and lysosomal trafficking of multiple mutant forms ofacid alpha-glucosidase. Hum. Mutat., 2009, 30(12), 1683-1692.
169. Khanna, R.; Soska, R.; Lun, Y.; Feng, J.; Frascella, M.; Young, B.; Brignol, N.; Pellegrino, L.; Sitaraman, S.A.; Desnick, R.J.; Benjamin, E.R.; Lockhart, D.J.; Valenzano, K.J. The pharmacological chaperone1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levelsin a mouse model of Fabry disease. Mol. Ther., 2010, 18(1), 23-33.
170. Hruska, K.S.; Goker-Alpan, O.; Sidransky, E. Gaucher disease andthe synucleinopathies. J. Biomed. Biotechnol., 2006, 2006(3), 78549.
171. Neumann, J.; Bras, J.; Deas, E.; O'Sullivan, S.S.; Parkkinen, L.; Lachmann, R.H.; Li, A.; Holton, J.; Guerreiro, R.; Paudel, R.; Segarane, B.; Singleton, A.; Lees, A.; Hardy, J.; Houlden, H.; Revesz, T.; Wood, N.W. Glucocerebrosidase mutations in clinicaland pathologically proven Parkinson's disease. Brain, 2009, 132(Pt7), 1783-1794.